

51. (NEW) The method of claim 42 wherein the tumor or cancer is a glioblastoma.
52. (NEW) The method of claim 42 wherein the tumor or cancer is a head and neck tumor.
53. (NEW) The method of claim 42 wherein the tumor or cancer is leukemia.
54. (NEW) The method of claim 42 wherein the tumor or cancer is a lymphoid malignancy.
55. (NEW) The method of claim 42 wherein the anti-ErbB2 antibody cross-blocks binding of antibody 4D5 (ATCC CRL 10463) to ErbB2.
56. (NEW) The method of claim 42 wherein the anti-ErbB2 antibody cross-blocks binding of antibody 7C2 (ATCC HB-12215) or antibody 7F3 (ATCC HB-12216) to ErbB2.
57. (NEW) The method of claim 42 further comprising combining a second therapeutic regimen with the administration of the anti-ErbB2 antibody.
58. (NEW) The method of claim 57 wherein the second therapeutic regimen is selected from the group consisting of (a) administration to the patient of a chemotherapeutic agent, anti-estrogen compound, anti-progesterone compound, an antibody against a tumor associated antigen other than ErbB2, a second different anti-ErbB2 antibody, a cytokine or a growth inhibitory agent in an amount effective to kill or inhibit growth of tumor cells in the patient, and (b) radiation therapy.
59. (NEW) The method of claim 58 wherein the second therapeutic regimen comprises administration to the patient of a chemotherapeutic agent in an amount effective to kill or inhibit growth of tumor cells in the patient.
60. (NEW) The method of claim 59 wherein the chemotherapeutic agent is selected from the group consisting of Doxorubicin, 5-Fluorouracil, Cytosine arabinoside ("Ara-C"), Cyclophosphamide, Thiotepa, Busulfan, Cytoxin, Methotrexate, Cisplatin, Melphalan, Vinblastine,

Bleomycin, Etoposide, Ifosfamide, Mitomycin C, Mitoxantrone, Vincristine, Vinorelbine, Carboplatin, Teniposide, Daunomycin, Carminomycin, Aminopterin, Dactinomycin, Mitomycins, Esperamicins, Melphalan and other related nitrogen mustards, tamoxifen and onapristone.

SJ B3
61. (NEW) The method of claim 57 wherein the second therapeutic regimen comprises administration to the patient of a growth inhibitory agent in an amount effective to inhibit growth of tumor cells in the patient.

62. (NEW) The method of claim 61 wherein the growth inhibitory agent is selected from the group consisting of vincas, topo II inhibitors, doxorubicin, daunorubicin, etoposide, bleomycin, DNA alkylating agents, tamoxifen, prednisone, dacarbazine, mechlorethamine, cisplatin, methotrexate, 5-fluorouracil, and ara-C.

63. (NEW) A method of treating a tumor or cancer characterized by overexpression or activation of ErbB2 comprising a first therapeutic regimen comprising administering an anti-ErbB2 antibody to a patient in an amount effective to kill or inhibit growth of tumor cells in the patient and a second therapeutic regimen comprising administering a growth inhibitory agent in an amount effective to inhibit growth of tumor cells in the patient, wherein the growth inhibitory agent is a vinca.

64. (NEW) The method of claim 63 wherein the vinca is selected from the group consisting of Vincristine, Vinblastine and Vinorelbine.

65. (NEW) The method of claim 63 wherein the anti-ErbB2 antibody cross-blocks binding of antibody 4D5 (ATCC CRL 10463) to ErbB2.

66. (NEW) The method of claim 63 wherein the anti-ErbB2 antibody cross-blocks binding of antibody 7C2 (ATCC HB-12215) or antibody 7F3 (ATCC HB-12216) to ErbB2.

67. (NEW) An article of manufacture comprising a container with an anti-ErbB2 antibody contained within the container and a label which indicates that the anti-ErbB2 can be used to treat a